Michael P. Doyle
Plus aucun poste en cours
Profil
Michael P.
Doyle worked as a Senior Director of Regulatory Affairs at Clovis Oncology, Inc. and as the Head of Regulatory Affairs at Novella Clinical, Inc. He also worked as the Vice President of Regulatory Affairs at Fresh Tracks Therapeutics, Inc. from 2016 to 2022.
Doyle holds a doctorate degree from the University of New Mexico School of Medicine.
Anciens postes connus de Michael P. Doyle
| Sociétés | Poste | Fin |
|---|---|---|
| FRESH TRACKS THERAPEUTICS, INC. | Conseiller Juridique Général | 01/07/2022 |
Novella Clinical, Inc.
 Novella Clinical, Inc. Miscellaneous Commercial ServicesCommercial Services For over a decade, Novella Clinical has been an active partner in supporting the biopharma and medical device industries with early phase through post-marketing development programs. Although their clinical experience is all-inclusive, the company's eClinical roots enable them to offer services that are specific to their clients' needs, often eliminating the demand to contract with multiple partners. From protocol development through final clinical study report - they integrate deep clinical expertise with industry-leading technologies and a proven approach to support, streamline and expertly resource the entire product development process. It focuses on quality customer service is reflected in their certification by Underwriters Laboratories on meeting global quality standards (ISO 9001:2008). | Conseiller Juridique Général | - |
| CLOVIS ONCOLOGY, INC. | Conseiller Juridique Général | - |
Formation de Michael P. Doyle
| University of New Mexico School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FRESH TRACKS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Novella Clinical, Inc.
Novella Clinical, Inc. Miscellaneous Commercial ServicesCommercial Services For over a decade, Novella Clinical has been an active partner in supporting the biopharma and medical device industries with early phase through post-marketing development programs. Although their clinical experience is all-inclusive, the company's eClinical roots enable them to offer services that are specific to their clients' needs, often eliminating the demand to contract with multiple partners. From protocol development through final clinical study report - they integrate deep clinical expertise with industry-leading technologies and a proven approach to support, streamline and expertly resource the entire product development process. It focuses on quality customer service is reflected in their certification by Underwriters Laboratories on meeting global quality standards (ISO 9001:2008). | Commercial Services |